MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
WENDELSHEIM, Germany–(BUSINESS WIRE)–MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today…